IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Han Ting Chang, et al.

Group Art Unit: 1713

Examiner Robert D. Harlan

Serial Number: 10/806,495 Filing Date: March 22, 2004

CONFIRMATION NO: 2769

Title: CROSSLINKED AMINE POLYMERS

FILED ELECTRONICALLY ON: NOVEMBER ________, 2006

Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97

Sir:

Applicant(s) hereby submit(s) an Information Disclosure Statement along with attached form(s) PTO/SB08. A copy of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.

Applicant(s) respectfully request(s) that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicant(s) further request(s) that the Examiner initial and return the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

A.	37 CF.	R §1.97(b). This Information Disclosure Statement should be considered by the Office				
		 It is being filed within 3 months of the filing date of a national application and is other than a continued prosecution application under §1.53(d); 				
		OR				
		(2) It is being filed within 3 months of entry of the national stage as set forth in $\S1.491$ in an international application;				
		OR				
		 It is being filed before the mailing of a first Office action on the merits; 				
		OR				
		(4) It is being filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.				
B.	B. 37 CFR \$1.97(e). Although this Information Disclosure Statement is being filed after the perispositifed in 37 CFR \$1.97(b), above, it is filed before the mailing date of the earlier of (1) a find foftice action under \$1.131, (2) a notice of allowance under \$1.311, (2) and action that otherwice protecution on the merits, this Information Disclosure Statement should be considered becau it is accompanied by one of:					
		a statement as specified in §1.97(e) provided concurrently herewith;				
		OR				
	⊠	a fee of \$180.00 as set forth in $\S1.17(p)$ authorized below, enclosed, or included with the payment of other papers filed together with this statement.				
C. 37 CFR §1.97(d). Although this Information Disclosure Statement is being filed after the mudate of the earlier of (1) a final office action under §1.113 or (2) a notice of allowance under §1 it is being filed before payment of the issue fee and should be considered because it is accomply:						
		i. a statement as specified in §1.97(e);				
		AND				
		 a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this Statement. 				
D.	☐ 37 CF	R §1.97(ε). Statement.				
		A statement is provided herewith to satisfy the requirement under 37 CFR §§1.97(c);				
		AND/OR				
		A statement is provided herewith to satisfy the requirement under 37 CFR §§1.97(d);				
		AND/OR				
		A copy of a dated communication from a foreign patent office clearly showing that the information disclosure statement is being submitted within 3 months of the filing date on the communication is provided in lieu of a statement under 37 C.F.R. § $1.97(e)(1)$ as provided for under MPEP 609 04(b) V.				
E.	☐ Statem disclosure	ent Under 37 C.F.R. §1.704(d). Each item of information contained in the information statement was first cited in a communication from a foreign patent office in a counterpart				

application that was received by an individual designated in § 1.56(c) not more than thirty (30) days

		its of 37 C.F.R. §1.704(d) to avoid reduction of the period of adjustment of the patent term int(s) delay.		
F.	37 CF	R §1.98(a)(2). The content of the Information Disclosure Statement is as follows:		
		Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed herewith.		
		OR		
	\boxtimes	Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08 are NOT enclosed.		
		AND/OR		
	\boxtimes	Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08 are enclosed in accordance with 37 CFR §1.98 (a)(2).		
		AND/OR		
		Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR §1.98(a)(2)(iii).		
G.	 37 CFR §1.98(a)(3). The Information Disclosure Statement includes non-English patents and references. 			
		Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.		
		Pursuant to MPEP 609(B), an English language copy of a foreign search report is submitted herewith to satisfy the requirement for a concise explanation where non-English language information is cited in the search report.		
		OR		
		☐ A concise explanation of the relevance of each patent, publication or other information provided that is not in English is as follows:		
	\boxtimes	Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation, or a portion thereof, of the non-English language reference(s) is provided herewith.		
H.	☐ 37 CFR §1.98(d). Copies of patents, publications and pending U.S. patent applications, or information specified in 37 C.F.R. § 1.98(a) are not provided herewith because:			
		Pursuant to 37 CFR §1.98(d)(1) the information was previously submitted in an Information Disclosure Statement for another application under which this application claims priority for an earlier effective filing date under 35 U.S.C. 120.		
		Application in which the information was submitted:		
		Information Disclosure Statement(s) filed on:		
		AND		
		The information disclosure statement submitted in the earlier application complied with		

paragraphs (a) through (c) of 37 CFR §1.98.

 \overline{\text{ Fee Authorization.}} The Commissioner is hereby authorized to charge the above-referenced fees
 of \$180.00\$ and charge any additional fees or credit any overpayment associated with this
 communication to Deposit Account No. 23-2415 (Docket, No. 29329-149.201).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: November 6 , 2006

650 Page Mill Road Palo Alto, CA 94304-1050 (650) 493-9300 Customer No. 56631

C:NrPariblPALIB1/ADC/2986279_LDOC Attorney Docket No. 29329-749.201

-4-

PTO/SB/08 (07/05)

Approved for use through 67/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/806,495	
			LOSURE	Filing Date	March 22, 2004	
			LICANT	First Named Inventor	Han Ting Chang	
			cessary)	Art Unit	1713	
				Examiner Name	Robert D. Harlan	
Sheet	1	Of	1	Attorney Docket Number	29329-749.201	

U.S. PATENT DOCUMENTS						
Exeminer Initials*	Cite Ne.1	Document Number Number-Kind Code ² (gl/known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lenes, Where Relevant Passages or Relevant Figures Appear	
	84.	US 5,607,669	03-04-1997	Mandeville III, et al.		
	85.	US 5,618,530	04-08-1997	Mandeville III, et al.		
	86.	US 5,679,717	10-21-1997	Mandeville III, et al.		
	87.	US 5,693,675	12-02-1997	Mandeville, III et al.		

FOREIGN PATENT DOCUMENTS Name of Patentos or Ferrigo Patent Document Country Code' - Number' - Knd Code' 6/2 Pages, Columns, Lines. Initials* MM-DD-YYYY Applicant of Cited Document Where Relevant Passages or Relevant Figures Appear WO 98/17707 AT The Dow Chemical 88 04-30-1998 Company Otsuka Pharmaceutica JP 1998059851A 03-03-1998 89. х Pactory Inc., et al. Otsuka Pharmaces JP 1998130154A 05-19-1998 Factory Inc., et al.

Examiner	Date	
Signature	Considered	
*EXAMINER Install if reference considered, whether or see cause	a is in confirmance with MPEP 609. Does fee through chance of rac in conformance and not considered. Include or	97

of this form with most communicate to applicate. "Applicant's using critical indication requires (approxim), "See Earth Codes of Life 2014 December 16 are to war super gar on 1912 of 1014. "Electro Office the instant for december 17 year from the result (4900 Stanler 1813). "The approximate communication contains the first part of their indication of the process of the communication of the december of the process of the communication of the december of the process of the communication of the december of the process of the communication of the december of the december of the december of the communication of the december of the

dock was kine finglish kappy. Tomform unstabl.

Man officer of devices a private plant of 10 Med 150. The Information is reported to detain or ratios in a least with in the first by the 150TO to provide its analysis. The officer of the information is a content of use of 150 Med 150 Med